Clinica Baviera

Clínica Baviera S.A. (Madrid: CBAV) is a Madrid-headquartered ophthalmology-clinic-chain operator founded in 1992 by Dr. Mauricio Costa, providing refractive-surgery (LASIK, ICL, presbyLASIK), cataract surgery, intraocular-lens implantation, and broader vision-correction-services. The company operates approximately 95 clinic-locations across Spain, Germany, Austria, Italy, and other European markets — the largest ophthalmology-clinic-chain in Spain and among the largest in Continental Europe.

The structural growth-trajectory: refractive-surgery-volumes have compounded approximately 6–9 percent annually since 2018, driven by aging-European-population-cataract-demand, presbyopia-correction-market-development, and increasing-corporate-and-private-insurance-coverage. 2017 acquisition by Aier Eye Hospital Group (Chinese-listed ophthalmology-leader Shenzhen: 300015, world's largest ophthalmology-clinic operator with approximately 600 clinics) provided strategic anchor and capital-allocation discipline. Aier retains approximately 50,3 percent of Clínica Baviera shares post-2017-tender-offer.

Clínica Baviera has a structurally-controlled shareholder-register dominated by Aier Eye Hospital Group. Aier Eye Hospital Group (Shenzhen: 300015) owns approximately 50,3 percent of shares — strategic-control-anchor since 2017 take-over. Other founding-family-and-management aligned holdings represent approximately 11 percent. Free-float is approximately 38–40 percent. Insider activity has been limited given the controlled-structure. Short-interest sits at approximately 1,8 percent of float as of May 2026 — very low, reflecting structural-defensive-quality narrative.

Clínica Baviera at 55,80 EUR per share with approximately 16,0 million shares outstanding has a market capitalization of approximately 894 million EUR. With minimal net-debt, enterprise value approximates the market-cap. Against trailing-twelve-month revenue of approximately 200 million EUR this translates to approximately 4,5x EV/sales.

On forward-earnings, Clínica Baviera trades at approximately 31,7x consensus fiscal-2026 EPS of approximately 1,76 EUR. Applying a peer-blended fair-multiple of 28–35x to base-case fiscal-2027 EPS of approximately 2,10 EUR produces a 12-month fair-value range of approximately 59–74 EUR per share — implying approximately 5–32 percent upside. The bear-case (Spanish recession, multiple compression) supports a 42–48 EUR range. The bull-case (15+ percent revenue growth sustained, Aier strategic-expansion) supports a 80–95 EUR range over 24 months. The 2,81 percent dividend yield adds defensive income-component.

1. 2026 Q3:

   H1 2026 earnings (early September 2026). Watch-items: refractive-surgery-volume growth, pricing-mix-progression, clinic-network-expansion update, dividend-payout-policy commentary.

2. 2027 Q1:

   Fiscal-2026 full-year results (early March 2027) plus fiscal-2027 guidance. Bullish 15+ percent revenue guidance plus Aier-strategic-expansion-update would unlock 65–75 EUR range.

3. 2027 H2:

   Half-year 2027 results plus any Aier-related strategic-update including potential European-clinic-acquisition program. Capital-markets-day update with multi-year guidance could unlock 75–85 EUR range.

Clínica Baviera is a defensive-quality Spanish-and-European ophthalmology-clinic-chain compounder with refractive-surgery-volume-compounding, Aier-Eye-Hospital-Group strategic-anchor providing capital-allocation discipline and Asia-Pacific expansion optionality, and 31,7x forward-P/E reflecting high-quality-growth-defensive premium. Position-sizing: 0,5–1,2 percent in quality-healthcare sleeve, suitable for investors with 3–5 year patience.